Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Tolerx and GSK partnered to develop and commercialize Tolerx's otelixizumab (formerly TRX4). Tolerx will be responsible
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury